Conference
Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).
Authors
Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Foo A; Leber B
Volume
28
Pagination
pp. 6564-6564
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.6564
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X